A lung cancer drug, developed by Cambridge’s Ariad Pharmaceuticals Inc before it was sold to Takeda Oncology, was approved for US sale Friday.
The small-molecule drug, to be marketed under the brand name Alunbrig, targets a subset of non-small cell lung cancer patients with a specific genetic mutation. About 20,000 people are diagnosed with the condition each year. The medicine won accelerated approval from the Food and Drug Administration.
“This has great potential for patients and for the company as well,” said Takeda Oncology president Christophe Bianchi. “We believe it’s the best-in-class agent that can improve the outcome for patients.”